Evidence map›Paper›PMID 42903585›Full record

ReviewhLife2026

Engineering organoids toward implantable living therapeutics.

Zhicheng Shi, Qianrong Yang, Xiaoyan You, Hui Wang, Hanjie Wang, Guoping Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in hLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhicheng ShiSchool of Life Sciences, Faculty of Medicine, Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, Tianjin University, Tianjin, China.
Qianrong YangSchool of Life Sciences, Faculty of Medicine, Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, Tianjin University, Tianjin, China.
Xiaoyan YouHenan University of Science and Technology, Henan, China.
Hui WangSchool of Life Sciences, Faculty of Medicine, Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, Tianjin University, Tianjin, China.
Hanjie WangSchool of Life Sciences, Faculty of Medicine, Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, Tianjin University, Tianjin, China.
Guoping ZhaoMaster Lab for Innovative Application of Nature Products, National Center of Technology Innovation for Synthetic Biology, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences (CAS), Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell-derived organoids are emerging as living therapeutics for repairing or replacing damaged tissues and organs, offering new opportunities for regenerative medicine. However, their clinical translation remains limited by immune rejection, insufficient functional integration, and low manufacturing throughput. In this review, we summarize recent advances in engineering organoids toward implantable living therapeutics by examining how hydrogel engineering, microfluidic chips, three-dimensional bioprinting, and synthetic biology overcome key translational barriers and facilitate the

Indexed as

bioengineeringclinical translationorganoidsregenerative medicinetransplantation

Identifiers

PMID42903585
PMCPMC13681718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.